Abstract: The present invention relates to nutritional compositions which are specifically designed to address the needs of infants and young children of at least 2 years of age. In particular, the invention provides a set of nutritional compositions for infants and young children, each nutritional composition having varying probiotic content. The set of the invention is specifically aimed at providing an optimal amount of probiotics to infants and young children over time and at each specific age.
Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.
Type:
Grant
Filed:
June 2, 2008
Date of Patent:
October 15, 2013
Assignee:
Puleva Biotech, S.A.
Inventors:
Rocio Martín Jiménez, Mónica Olivares Martín, Esther Antonia Jiménez Quintana, Maria Luisa Marín Martínez, Saleta Sierra Ávila, Antonio Maldonado Barragán, Virginia Martín Merino, Francesc Blanch Martell, Celina Torre Lloveras, Federico Lara Villoslada, Rebeca Arroyo Rodríguez, Julio Boza Puerta, Jesús Jiménez López, Leónides Fernández Álvarez, Odón Julían Sobrino Abuja, Jordi Xaus Pei, Juan Miguel Rodríguez Gómez, Susana Delgado Palacio
Abstract: Bifidobacterium strain AH1206 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity for example undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
October 15, 2013
Assignee:
Alimentary Heath Limited
Inventors:
John MacSharry, Liam O'Mahony, David O'Sullivan, Barry Kiely
Abstract: The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula I wherein one of Y1 and Y2 is S, SO or SO2 and the other is CH2; L is a direct bond or methylene; A1 and A2 are C—H, or one of A1 and A2 is C—H and the other is N; R1 is hydrogen or methyl; R2 is chlorodifluoromethyl or trifluoromethyl; R3 is 3,5-dibromo-phenyl, 3,5-dichloro-phenyl, 3,4-dichloro-phenyl, or 3,4,5-trichloro-phenyl, 3,5-dichloro-4-fluoro-phenyl, or 3,5-bis-trifluoromethylphenyl; R4 is methyl or chlorine; R5 is hydrogen; or R4 and R5 together form a bridging 1,3-butadiene group; and wherein component B is an insecticide. The invention also relates to methods of controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest a combination of components A and B.
Type:
Application
Filed:
December 15, 2011
Publication date:
October 10, 2013
Applicant:
SYNGENTA PARTICIPATIONS AG
Inventors:
Peter Renold, Jerome Yves Cassayre, Myriem El Qacemi, Jagadish Pabba, Thomas Pitterna
Abstract: A method of treating and protecting a subject from endotoxin shock by administering a composition including hydrogen, releasing hydrogen in the subject, and down-regulating production of TNF-? and IL-6. A method of treating inflammation in a subject. A method of suppressing hydroxyl radical in a subject. A method of treating inflammation in a subject. A method of reducing the basal level of phosphorylation of MAPKs in non-stimulated monocyte lineage cells in a subject. Methods of performing drug screen tests for compounds that can treat the above conditions. A diagnostic method for diagnosing patients with diseases caused by the MAPK pathway.
Type:
Application
Filed:
September 2, 2011
Publication date:
October 10, 2013
Inventors:
Toshihisa Kawai, Mikihito Kajiya, Kimihiro Sato
Abstract: The invention relates to a preparation of metabolically active bacteria, compositions comprising such a preparation, e.g., probiotic supplements or animal feeds, and to uses thereof, for example in the treatment of diseases affecting the intestinal microbial balance. Also described are a growth substrate for microorganisms comprising a mixture of complex and simple sugars and a process for the manufacture of preparations of metabolically active microorganisms using this growth substrate.
Abstract: Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R1, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
Type:
Grant
Filed:
January 30, 2009
Date of Patent:
October 8, 2013
Assignee:
E.I. du Pont de Nemours and Company
Inventors:
Caleb William Holyoke, Jr., My-Hanh Thi Tong, Reed Aaron Coats, Wenming Zhang, Stephen Frederick McCann, Dominic Ming-Tak Chan
Abstract: The present invention relates to a bifidobacterium adolescentis SPM0212 having antiviral activity for hepatitis B virus, and a pharmaceutical composition for preventing and treating hepatitis B comprising thereof. The bifidobacterium adolescentis SPM0212 or its fraction of the present invention shows antiviral activity for hepatitis B virus by blocking the production of antigen s of hepatitis B virus, and by inhibiting the expression of DNA, RNA and HBsAg of the HBV.
Type:
Application
Filed:
June 5, 2013
Publication date:
October 3, 2013
Applicant:
SAHMYOOK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION
Abstract: The present invention is to obtain capsules which do not disintegrate in stomach and intestine after orally administrating them and which disintegrate specifically in large intestine. The present invention thus provides a capsule which disintegrates specifically in large intestine, comprising a content comprising a main agent, and a shell, covering the content, comprising a natural water-soluble polymer as a shell base material and chitosan powder dispersing in the natural water-soluble polymer.
Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.
Abstract: Suggested is a compound of the formula (X) or any salt of a compound of the formula (X) or any mixture containing or consisting of two or more different compounds of the formula (X), two or more different salts of compounds of the formula (X) or one or more different compounds of the formula (X) and one or more different salts of compounds of the formula (X), wherein for R1, R2 and R3 independently of one another in every compound of the formula (X) the following applies: R1 means hydrogen or methyl, R2 means an organic residue with 5 carbon atoms and one oxygen atom or none and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, or R1 and R2 together with the carbon atoms in positions 4 and 5 and the oxygen atom bound to the carbon atom in position 4 form a ring and comprise 5 carbon atoms and one oxygen atom or none, and R3 means an organic residue with 10 carbon atoms and one or more oxygen atoms, for use in a method for the prophylaxis and/or treatment of inflammation.
Type:
Application
Filed:
March 1, 2013
Publication date:
September 26, 2013
Applicant:
Symrise AG
Inventors:
Jakob Ley, Katharina Reichelt, Marcus Götz, Maria Blings, Veronika Somoza, Jessica Walker, Joel Michael Walker
Abstract: The present invention relates to a method for preparing a suspension for the encapsulation of heat and moisture sensitive substances in capsules, sachets, droplets and food compositions. It also relates to methods for encapsulating, to the encapsulated products and to methods for storing the encapsulated products. The invention is extremely suitable for the encapsulation of microbial cultures. Cultures encapsulated in capsules prepared according to the method of the invention, will stay stable for a long time. At 25 degrees C. they show a stability reduction of less than 1 log per month.
Type:
Application
Filed:
May 23, 2013
Publication date:
September 26, 2013
Applicant:
DSM ASSETS B.V.
Inventors:
Ray Edward KOWALSKI, Shan-Shan SHEU, Abdul RASHID, Caroline BRONS, Elizabeth NASCIMENTO
Abstract: The invention discloses a composition comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.
Abstract: A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.
Type:
Grant
Filed:
November 27, 2012
Date of Patent:
September 24, 2013
Assignee:
TNTGamble, Inc.
Inventors:
Christopher London, Stephen J. Turner, Tanya Borek, Catherine Federici, Michael P. Hite
Abstract: Bacteria thyA(?) mutants with increased vitamin K and use of these thyA(?) mutants for making a composition/product for treatment and/or prevention of vitamin K deficiency in a mammal (e.g. a human).
Abstract: The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolysed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.
Abstract: The invention relates to certain compounds, salts of these compounds and mixtures containing or consisting of two or more such compounds, two or more such salts or one or more such compounds and one or more such salts, each for use in a method for the prophylaxis and/or treatment of inflammation, in particular of inflammation of the skin.
Type:
Application
Filed:
February 27, 2013
Publication date:
September 12, 2013
Applicant:
Symrise AG
Inventors:
Katharina Reichelt, Jakob Ley, Marcus Götz, Maria Blings
Abstract: The present invention is an oral dosage composition for prevention and treatment of hepatic inflammation such as NASH. The present invention is an oral dosage composition for prevention or treatment of hepatic inflammation, contains the radical scavenging active spirulina powder effective in preventing, ameliorating, and curing NASH or the like.
Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
Type:
Application
Filed:
April 17, 2013
Publication date:
September 12, 2013
Applicant:
EnGeneIC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: The inventions discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in preventing acute respiratory infections (ARI) and/or relieving symptoms of said ARI infections. Preferably said composition is a starter infant formula. Said acute respiratory infection is in particular bronchiolitis or otitis.
Abstract: The invention discloses an oligosaccharide mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide, 5-90 wt % of at least one neutral oligosaccharide, 2-50 wt % of at least one sialylated oligosaccharide, and/or 5-70 wt % of at least one fucosylated oligosaccharide. The invention also discloses a food product, especially an infant formula, comprising said oligosaccharide mixture.
Abstract: Bacteria which co-express protease inhibitors and protease sensitive therapeutic agents, which are surface displayed, secreted and/or released and result in their localized production and maintenance within a target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. Protease sensitivity may be further accomplished by engineering protease degradation sites within the therapeutic agents, further enhancing the inactivation outside of the target tissue while retaining activity within the target tissue through co-expression of a protease inhibitor. Novel chimeric proteins secreted by bacteria, including chimeric toxins targeted to neoplastic cells, tumor matrix cells and cells of the immune system, and combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described.
Abstract: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
Type:
Application
Filed:
February 28, 2013
Publication date:
August 29, 2013
Applicants:
The General Hospital Corporation D/B/A Massachusetts General Hospital, ETHICON ENDO-SURGERY, INC.
Inventors:
ETHICON ENDO-SURGERY, INC., The General Hospital Corporation D/B/A Massachusetts General Hospital
Abstract: The invention provides an ingredient containing shelf-stable probiotic microorganisms for use in preparing probiotic food products requiring long shelf-life. The ingredient is prepared by coating particles or an agglomeration thereof with a suspension of osmotically shocked probiotic microorganisms and drying the product.
Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from infections. The subject matter of the present inventions allows it to reduce absence from school or daycare. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of infections in children to reduce absence from school or daycare.
Type:
Application
Filed:
November 9, 2011
Publication date:
August 29, 2013
Applicant:
NESTEC S.A.
Inventors:
Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: The present invention relates to the field of drinkable yoghurt compositions. In particular, the present invention provides drinkable yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic micro-organisms.
Type:
Application
Filed:
November 7, 2011
Publication date:
August 29, 2013
Applicant:
Single Buoy Moorings, Inc
Inventors:
Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: The present invention relates to the field of powdered cereal compositions to be reconstituted in milk, infant formula or water. In particular, the present invention relates to powdered cereal compositions to be administered to infants or young children. The powdered cereal compositions may be used to strengthen the immune system and/or to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to a powdered cereal composition comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms.
Type:
Application
Filed:
November 2, 2011
Publication date:
August 29, 2013
Applicant:
NESTEC S.A.
Inventors:
Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from sunflower oils). The weight ratio of omega 6 fatty acids to omega 3 fatty acids is 10:1 to 1:1, with 10:1 to 5:1 being preferred for normal animals and 2:1 to 1:1 being preferred for animals which have fatty acid responsive conditions. The second component is the GI component, which is used for facilitating animal gut health. This component includes prebiotics, probiotics and immunoglobulin (typically from albumin concentrate). The third component is the breed specific component and can include vitamins, minerals, additional fatty acids, antioxidants, amino acids, palatants, and nutraceutical additives.
Type:
Application
Filed:
February 3, 2012
Publication date:
August 22, 2013
Inventors:
Melinda Fernyhough Culver, Alison Weber, Marta Draper, Tom Myers
Abstract: The invention relates to the use of lactic acid bacteria, for use in improving transepithelial resistance and more particularly in treating and/or preventing constipation and/or irritable bowel disease.
Abstract: The present invention relates to a method of producing rough strains of a bacterium, such as Mycobacterium obuense, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4?-Diaminodiphenyl sulfone or an analogue thereof). A rough strain of Mycobacterium obuense producible by said method and uses thereof. In particular, uses of a rough strain of Mycobacterium obuense deposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.
Type:
Grant
Filed:
December 5, 2011
Date of Patent:
August 20, 2013
Assignee:
Bioeos Limited
Inventors:
John Lawson Stanford, Cynthia Ann Stanford, Graham McIntyre, Oscar Adelmo Bottasso
Abstract: The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
Type:
Application
Filed:
March 27, 2013
Publication date:
August 15, 2013
Applicants:
University College Cork, National University of Ireland, Cork, Alimentary Health Ltd., TEAGASC - The Agriculture and Food Development Authority
Inventors:
University College Cork, National University of Ireland, Cork, TEAGASC - The Agriculture and Food Development Authority, Alimentary Health Ltd.
Abstract: The invention relates to lactocepins and/or a functionally active fragment thereof for use in the prophylaxis and/or the treatment of a disease and to one or more lactocepin(s) and/or one or more functionally active fragment(s) thereof for use in the prophylaxis and/or treatment of IP-10-mediated inflammatory diseases.
Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
Abstract: The purpose of the present invention is to provide a technique whereby the flavor of products such as fermented milk that use the Bifidobacterium bacteria can be improved while maintaining the effect of the Rubus suavissimus S. Lee for improving the viability of the Bifidobacterium bacteria. Provided is a fermented food that includes: a Rubus suavissimus S. Lee essence obtained as a concentrate through electrodialyzing a Rubus suavissimus S. Lee extract added with an inorganic salt; and bacteria of the genus Bifidobacterium. Also provided is a method for producing such fermented foods.
Abstract: Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium lividum and a pharmaceutically acceptable carrier. Probiotic composition(s) and/or process(es) thereof may include relatively heat tolerant Janthinobacterium lividum which may produce metabolites, for example violacein up to approximately 29° C. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividum between approximately 25×106 and 6.4×107 cells. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium lividum which has and/or produces between approximately 18 ?M and 129 ?M of violacein. Probiotic composition(s) and/or process(es) thereof may include a stimulant to maximize metabolites.
Abstract: This invention relates to LAP-expressing probiotic bacteria and methods of use thereof to prevent and treat a pathogenic bacterial infection.
Abstract: The invention relates to microorganisms for the treatment of food allergies, specifically coeliac disease, as well as to methods for the selection thereof. The action mechanisms of said microorganisms include: (i) the regulation of the innate and adaptive immunological responses; (ii) the reduction of the concentration of toxic gluten peptide epitopes in the intestinal lumen; (iii) the strengthening of the barrier defence function against harmful antigens and bacteria; and (iv) the provision of enzymatic activities that promote digestion.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
August 6, 2013
Assignee:
Consejo Superior de Investigaciones Cientificas
Inventors:
Yolanda Sanz Herranz, Esther Sanchez Sanchez, Marcela Susana Medina, Giada De Palma, Inmaculada Nadal Gimenez
Abstract: There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or variant thereof, a nucleic acid encoding the C. perfringens antigenic polypeptide or variant thereof, or a recombinant cell producing the C. perfringens antigenic polypeptide or variant thereof.
Type:
Grant
Filed:
May 30, 2008
Date of Patent:
August 6, 2013
Assignee:
The University of Guelph
Inventors:
John Prescott, Raveendra Kulkarni, Valeria Parreira, Shayan Sharif
Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
Abstract: The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.
Type:
Application
Filed:
July 26, 2011
Publication date:
August 1, 2013
Applicant:
SUOMEN PUNAINEN RISTI VERIPALVELU
Inventors:
Pirjo Wacklin, Jaana Matto, Harri Makivuokko, Jukka Partanen, Janne Nikkila
Abstract: In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
Abstract: The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease.
Type:
Application
Filed:
May 27, 2011
Publication date:
August 1, 2013
Applicant:
COMPAGNIE GERVAIS DANONE
Inventors:
Sophie Legrain-Raspaud, Gianfranco Grompone, Sandrine Capronnier, Isabelle Chambaud, Tamara Smokvina, Marie-Christine Degivry, Biliana Lesic, Michel Neunlist
Abstract: A cellular constituent is lysed from, produced by and/or isolated from one or more bacteria from the genus Bacteroides, and the cellular constituent, a derivative thereof, and/or one or more bacteria from the genus Bacteroides, or a modified form thereof, is employed in compositions and methods for modulating an inflammatory response.
Abstract: Compositions and methods useful for reducing or eliminating the presence of pathogens in meat or meat products are disclosed. Administration of one or more lactic acid producing microorganisms to a live animal, to a carcass, to meat, to meat products, or in animal feed results in significant reductions in the amount of pathogens potentially harmful to humans when ingested. Synergistic effects can be achieved with the administration of multiple strains of microorganisms.
Abstract: An anti-obesity agent or a glucose tolerance-ameliorating agent containing a bacterium belonging to the genus Bifidobacterium as an active ingredient, wherein the bacterium belonging to the genus Bifidobacterium exhibits a conversion rate from linoleic acid into conjugated linoleic acid of not more than 10%. The present invention is able to provide an anti-obesity agent and a glucose tolerance-ameliorating agent that are effective for the prevention or treatment of obesity or the amelioration of glucose tolerance and also exhibit superior safety, as well as providing foods or beverages containing these agents. Further, the present invention is also able to provide a bacterium of the genus Bifidobacterium, and in particular a Bifidobacterium breve, that is effective for the prevention or treatment of obesity or the amelioration of glucose tolerance and also exhibits superior safety, as well as providing a pharmaceutical composition containing this bacterium.
Abstract: Methods are disclosed for the prevention and/or treatment of certain gastrointestinal (GI) diseases, such as Johne's Diseases (JD) in animals and Crohn's Disease (CD) in human. Administration of certain probiotic bacteria, such as lactic acid producing bacteria, to animals helps inhibit GI infection by Mycobacterium avium subsp. paratuberculosis (MAP). MAP is the primary pathogenic agent suspected of causing various inflammatory bowel diseases in cattle or humans.
Abstract: This invention provides compounds of Formula 1, N-oxides and suitable salts thereof wherein R1 is Me, Cl, Br or F; R2 is F, Cl, Br, C1-C4 haloalkyl or C1-C4 haloalkoxy; R3 is F, Cl or Br; R4 is H; C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C3-C5 cycloalkyl, or C4-C6 cycloalkylalkyl, each optionally substituted with one substituent selected from the group consisting of halogen, CN, SMe, S(O)Me, S(O)2Me, and OMe; R5 is H or Me; R6 is H, F or Cl; and R7 is H, F or Cl. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide thereof or a suitable salt of the compound (e.g., as a composition described herein).
Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.
Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.